Non-hemorrhagic imaging markers of cerebral amyloid angiopathy in memory clinic patients.

ABSTRACT:

Introduction

The Boston criteria v2.0 for cerebral amyloid angiopathy (CAA) incorporated non-hemorrhagic imaging markers. Their prevalence and significance in patients with cognitive impairment remain uncertain.

Methods

We studied 622 memory clinic patients with available magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers. Two raters assessed non-hemorrhagic markers, and we explored their association with clinical characteristics through multivariate analyses.

Results

Most patients had mild cognitive impairment; median age was 71 years and 50% were female. Using the v2.0 criteria, possible or probable CAA increased from 75 to 383 patients. Sixty-eight percent of the sample had non-hemorrhagic CAA markers, which were independently associated with

SUBMITTER: Costa AS 

PROVIDER: S-EPMC11247708 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature